Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Haohai Biological Technology Co (FRA:5HB) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Shanghai Haohai Biological Technology Co's Enterprise Value for the quarter that ended in Mar. 2026 was €293.5 Mil.
Shanghai Haohai Biological Technology Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €14.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Haohai Biological Technology Co EV-to-EBIT Related Terms
Shanghai Haohai Biological Technology Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Haohai Biological Technology Co EV-to-EBIT Chart
Shanghai Haohai Biological Technology Co Annual Data
FRA:5HB vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Shanghai Haohai Biological Technology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Haohai Biological Technology Co EV-to-EBIT vs Biotechnology Industry
Shanghai Haohai Biological Technology Co's current Enterprise Value is €604.1 Mil.
Shanghai Haohai Biological Technology Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €14.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Haohai Biological Technology Co (FRA:5HB) has a EV-to-EBIT of 42.48 as of Aug. 18, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Shanghai Haohai Biological Technology Co and its competitors. This is 295% above median its historical median of 10.76. Over the past decade, Shanghai Haohai Biological Technology Co's EV-to-EBIT has ranged from 5.63 to 50.68. According to the industry distribution chart, Shanghai Haohai Biological Technology Co ranks #288 out of 370 companies in the Biotechnology industry, placing it in the top 77.8%.
Is Shanghai Haohai Biological Technology Co's EV-to-EBIT too high?
Shanghai Haohai Biological Technology Co's current EV-to-EBIT of 42.48 is 295% above median its 10-year median of 10.76. Over the past 10 years, this metric has ranged from a low of 5.63 to a high of 50.68. The Biotechnology industry median EV-to-EBIT is 16.28. Shanghai Haohai Biological Technology Co's value of 42.48 is 161% above this industry median. Based on the distribution chart, Shanghai Haohai Biological Technology Co ranks #288 out of 370 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Shanghai Haohai Biological Technology Co has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Haohai Biological Technology Co's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Haohai Biological Technology Co ranks #288 out of 370 companies for EV-to-EBIT. This places Shanghai Haohai Biological Technology Co in the lower half of its industry. The industry median EV-to-EBIT is 16.28. Shanghai Haohai Biological Technology Co's value of 42.48 is 161% above this benchmark. Historically, Shanghai Haohai Biological Technology Co's own EV-to-EBIT has ranged from 5.63 to 50.68 over the past decade. While the company's 10-year median is 10.76 vs. the industry median of 16.28, Shanghai Haohai Biological Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 16.28, based on 370 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Haohai Biological Technology Co's current EV-to-EBIT of 42.48 is 161% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Shanghai Haohai Biological Technology Co and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 16.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Haohai Biological Technology Co's current EV-to-EBIT is 42.48, which is 295% above median its own 10-year median of 10.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Haohai Biological Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co (FRA:5HB) is currently considered Significantly Undervalued. The stock's GF Value™ is €2.85, compared to a current price of €1.79 — trading 37.2% below its estimated fair value. The current EV-to-EBIT is 42.48, which is 295% above median its 10-year median of 10.76 and 161% above the Biotechnology industry median of 16.28. Shanghai Haohai Biological Technology Co's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Shanghai Haohai Biological Technology Co (FRA:5HB), the current EV-to-EBIT is 42.48 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Haohai Biological Technology Co (FRA:5HB) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co stock appears to be undervalued.
The current stock price of €1.79 is trading 37.2% below its estimated GF Value™ of €2.85.
GuruFocus considers Shanghai Haohai Biological Technology Co to be Significantly Undervalued.
Key valuation signals for FRA:5HB:
EV-to-EBIT: 42.48 (295% above median its 10-year median of 10.76)
GF Value™: €2.85 vs. price of €1.79 (37.2% below fair value)
Industry Position: 161% above the Biotechnology median (#288 of 370)
No single metric tells the full story. See the FRA:5HB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. The Company's operating activities are related to a single operating segment, which is the manufacture and sale of biologicals, medical hyaluronate, and intraocular lenses, research and development of biological engineering and pharmaceutical products, and the provision of related services. Its products are categorized into four types, comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China, which is the key revenue driver, the United States, the United Kingdom, and other countries.
66GF Score
Get the complete analysis for FRA:5HB
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5HB has been successfully added to your 
